CVC (COVID-19 Vaccine Corporation Ltd.) is developing a unique vaccine approach that is designed to protect against both current and future infections by SARS-CoV-2 viruses. As the COVID-19 pandemic progresses, we are seeing the emergence of a number of variants such beta, delta, lambda and omicron, where existing vaccines may not be as efficacious.

CVC believes we should look to the future and be ready for unforeseen variants rather than react retrospectively to variants once they arise.

CVC has been set up by four individuals in New Zealand who are all experts in their pharmaceutical and biotechnology fields. Expertise includes vaccine development and production.

Early results generated by CVC are encouraging, so CVC is progressing its technology as rapidly possible.